Celgene's Multiple Myeloma Triplet Succeeds in Key Phase III Trial Post author:Sam Post published:February 5, 2018 Post category:BioPharma The international clinical study, OPTIMISMM, achieved its primary endpoint. Source: BioSpace You Might Also Like ImmunoGen Stock Climbs on Positive Ovarian Cancer Data March 25, 2018 2 Biotech Stocks That Exploded 500%+ in the Last 3 Years June 25, 2017 Genentech Dumps Another $650M in New Haven Biotech Arvinas November 14, 2017
